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Abstract
 Background—Because of advancements in care, there has been a decline in mortality from 
congenital heart defects (CHD) over the last several decades. However, there are no current 
empirical data documenting the number of people living with CHD in the United States (US). Our 
aim was to estimate the CHD prevalence across all age groups in the US in the year 2010.
 Methods—The age-, sex-, and severity-specific observed prevalence of CHD in Québec, 
Canada in the year 2010 was assumed to equal the CHD prevalence in the non-Hispanic white 
population in the US in 2010. A race-ethnicity adjustment factor, reflecting differential survival 
Correspondence to: Suzanne Gilboa, PhD, MHS, National Center on Birth Defects and Developmental Disabilities, Centers for 
Disease Control and Prevention, MS E-86; 4770 Buford Highway, Atlanta, GA 30341, Tel: 404-498-4425, sgilboa@cdc.gov. Ariane 
Marelli MD, MPH, FRCPC, FACC, FAHA, Professor of Medicine, McGill University, Founder and Director, McGill Adult Unit for 
Congenital Heart Disease, Director of Research, Associate Director of Academic Affairs, Cardiology, McGill University Health 




The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers 
for Disease Control and Prevention.
HHS Public Access
Author manuscript
Circulation. Author manuscript; available in PMC 2017 July 12.
Published in final edited form as:













between racial-ethnic groups through age 5 for persons with a CHD and that in the general US 
population, was applied to the estimated non-Hispanic white rates to derive CHD prevalence 
estimates among US non-Hispanic blacks and Hispanics. Confidence intervals for the estimated 
CHD prevalence rates and case counts were derived using a combination of Taylor series 
approximations and Monte Carlo simulation.
 Results—We estimated that approximately 2.4 million people (1.4 million adults, 1 million 
children) were living with CHD in the US in 2010. Nearly 300,000 of these individuals had severe 
CHD.
 Conclusions—Our estimates highlight the need for two important efforts: (1) planning for 
health services delivery to meet the needs of the growing population of adults with CHD and; (2) 
the development of surveillance data across the lifespan to provide empirical estimates of the 
prevalence of CHD across all age groups in the US.
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Congenital heart defects (CHD) are diagnosed in approximately 8–10 per 1,000 live births in 
the United States (US).1,2 CHD are associated with lifelong comorbidity and health services 
utilization and the need for repeated surgical interventions3 has resulted in a significant 
increase in health services utilization during infancy and childhood,4 transition years,5 and 
adulthood.6 In the US in 2004, CHD accounted for more than 46,000 hospitalizations among 
individuals of all ages and nearly $1.4 billion in hospital costs.7
Advances in medical and surgical treatment have led to decreased mortality attributable to 
CHD across all age groups in the US.8–11 With lower mortality, a demographic shift in the 
population living with CHD is likely. The most compelling evidence of this demographic 
shift comes from recent analyses of administrative data in Québec. Analyses of these data 
were the first to show time trends in the lifetime CHD prevalence in the general population, 
documenting a 22% increase in the number of children and 85% increase in the number of 
adults living with severe CHD between the years 1985 and 2000.12,13 The median age at 
death among those with severe CHD has reportedly increased from two years of age in 
1987–1993 to 23 years of age in 1999–2005.14 Similar demographic trends are expected to 
exist in other high-income countries, including the US, but observation of such patterns in 
the US is challenging in the absence of population-based surveillance systems with long-
term follow-up, or extensively linked administrative datasets.
Two previous publications estimated the size of the adult population living with CHD in the 
US in the year 2000 based on estimates of birth prevalence and survival.15,16 In 2001, a task 
force of the American College of Cardiology estimated approximately 788,000 adults with 
CHD were living in the US in the year 2000.16 In a 2004 analysis, this estimate was refined 
based on survival probabilities considering either treatment or no treatment, resulting in a 
range – from 650,000 without treatment to 1,330,000 with treatment.15 In 2009, Marelli and 
colleagues estimated that 860,000 adults with CHD were living in the US in the year 2000, 
based on an extrapolation of the prevalence estimates from the year 2000 in Québec.13 
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Evidence-based planning for health services delivery to meet the needs of the growing 
population of adults with CHD in the US will depend on the availability of contemporary 
data on prevalence of CHD across the lifespan. The goal of the current study was to provide 
estimates of the prevalence of CHD across all age groups in the US in the year 2010.
 METHODS
Based on the recently published estimates of the age-, sex- and severity-specific prevalence 
of CHD in Québec, Canada,17 we assumed that the Québec CHD prevalence within age and 
sex strata was equal to that in similar strata in the non-Hispanic white population in the 
United States in 2010. We then applied a race-ethnicity adjustment factor to derive CHD 
prevalence estimates for the U.S. non-Hispanic Black and Hispanic populations based on the 
non-Hispanic white estimates. A detailed description of the methods, assumptions and 
derivation of the estimators used in developing the U.S. CHD prevalence estimates is given 
in the Supplemental Material. A complete list of assumptions can be found in Supplemental 
Table 1.
 Data Inputs
 CHD Prevalence in Québec in 2010—Age-, sex- and severity-specific prevalence of 
CHD in Québec in 2010 were calculated from the Québec Congenital Heart Disease 
Database, based on 28 years of longitudinally-linked administrative data. Detailed methods 
for the development of these estimates are published.17 Access to health care is universal in 
Québec and every individual is assigned a unique medical record number in the first year of 
life that is used to track all diagnoses and health services delivered. These interactions with 
the health care system are recorded across several administrative databases including 
physicians’ services and drug claims, hospital discharges, health insurance, and the death 
registry. The Québec Congenital Heart Disease Database was created by linking the relevant 
databases for all Québec patients with at least one diagnostic or procedural code for a CHD 
who came into contact with the healthcare system in Québec from January 1, 1983, to 
December 31, 2010 (inclusive).17 Diagnostic codes adhered to the International 
Classification of Disease-9th Revision (ICD-9) and 10th Revision (ICD-10; as of 2006). 
Severe CHD were defined based on these code systems as definitive diagnoses or surgical 
procedures to treat the following CHD types: tetralogy of Fallot, truncus arteriosus, 
complete and congenitally corrected transposition of the great arteries, atrioventricular septal 
defect, or univentricular hearts.12,17 Severe CHD and all other CHD diagnoses were 
included in estimates for all CHD. CHD prevalence in Québec in 2010 was calculated as the 
total number of persons living with CHD as of midyear per 1,000 population. Children were 
defined as individuals aged less than 18 years; adults were 18 years and older. (Supplemental 
Table 2)
 US Population in the Year 2010 and Racial-Ethnic-Specific CHD Survival and 
All-Cause Mortality—Age-, sex- and racial-ethnic-specific estimates for the size of the 
US population were derived from the July 1, 2010 US Census Bureau intercensal estimates 
(http://www.census.gov/popest/data/intercensal/national/files/US-EST00INT-
ALLDATA.pdf; Accessed November 11, 2011)). Racial-ethnic differences in CHD mortality 
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were estimated for children 0–5 years of age based on published estimates of 5-year survival 
among non-Hispanic white, non-Hispanic black and Hispanic children with specific CHD 
using data from the Texas Birth Defects Registry.18 The published survival data were 
aggregated by the authors (WNN, PX) into groupings of all CHD and severe CHD to 
correspond to the prevalence data available from Québec. Racial-ethnic differences in all-
cause mortality for children 0–5 years of age were derived from 1999–2014 detailed 
mortality data available from CDC WONDER (Wide-ranging Online Data for 
Epidemiologic Research).19 (Supplemental Tables 3 and 4).
 Statistical Analysis
The Figure is a flowchart illustrating the input data and steps in the estimation process. As a 
first step in the estimation process, we used the CHD age-, sex-, and severity-specific 
prevalence estimates in Québec in 2010 as estimates for the corresponding age-, sex- and 
severity CHD prevalence in the 2010 among the US non-Hispanic white population, We then 
estimated race-ethnicity adjustment factors that, under some simplifying assumptions 
(Supplemental Table 1), correspond to the ratio of CHD prevalence among either non-
Hispanic blacks to non-Hispanic whites or Hispanics to non-Hispanic whites. Therefore, 
multiplying the estimated non-Hispanic white CHD prevalence by the appropriate 
adjustment factor results in estimate of CHD prevalence within the other racial-ethnic 
populations. A detailed rationale for the estimator for the race-ethnicity adjustment factor is 
provided in the Supplemental Material, however, the key assumptions underlying this 
approach are that U.S. birth prevalence of CHD does not differ among the racial-ethnic 
groups considered in this analysis and that survival probability within racial-ethnic groups 
among those born with a CHD and the U.S. general population differs only though age 5.
We used a combination of Taylor series approximations and Monte Carlo simulation, in 
which the model inputs were repeatedly drawn from their assumed sampling distributions, to 
estimate the sampling variability for the U.S. CHD prevalence and case count estimates. 
While the U.S. Census-based population counts were considered fixed, all other inputs to the 
model, observed prevalence from Québec, mortality among persons with a CHD observed in 
the Texas Birth Defect Registry and death counts from the detailed mortality file, were 
considered to be subject to sampling variability. Standard errors for these inputs were 
estimated under a Poisson assumption on the number of CHD cases or number of deaths as 
appropriate. The sampling distributions for these inputs were assumed to be normal with 
mean equal to the observed value and variance equal to the square of the estimated standard 
error. The Monte Carlo simulation process was repeated 10,000 times with CHD prevalence 
and case count estimates for each repetition calculated based on values for the model inputs 
drawn from their assumed sampling distributions in each iteration. The resulting 10,000 
calculated values for CHD prevalence and case counts were assumed to reflect the sampling 
variability of the estimators. These generated sampling distributions for U.S. CHD 
prevalence and cases counts are summarized using the mean value and 95% confidence 
intervals defined by the 2.5th percentile and 97.5th percentile of the generated values. To 
reflect the lack of certainty in these modeled estimates, all CHD case count estimates are 
rounded to the nearest 1,000. A detailed description of the methods used to estimate the 
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sampling error in the CHD estimates is provided in the Supplemental Material. This study 
did not involve human subjects and is exempt from Institutional Review Board review.
 RESULTS
Approximately 2.4 million people were estimated to be alive with CHD in the US in 2010 
(Table 1). Approximately 290,000 (12%) of these individuals had severe CHD. The 
prevalence of CHD ranged from approximately 6 per 1,000 in adults to 13 per 1,000 in 
children although there are more adults estimated to be living with CHD (approximately 1.4 
million) compared to children (approximately 1 million). Considering differences by race-
ethnicity, the prevalence was slightly higher in the non-Hispanic white and Hispanic 
population compared with the non-Hispanic black population. Given the relative sizes of the 
US population, however, the vast majority of individuals estimated to be living with CHD in 
the US are non-Hispanic white (approximately 1.7 million) compared with non-Hispanic 
black or Hispanic (approximately 700,000).
Overall, there was a slight predominance of females compared to males (Table 2). The most 
striking difference between the sexes was among individuals 25–44 years of age; women in 
this age group had a prevalence of 6 per 1,000 while men had a prevalence of 3.8 per 1,000 – 
which translated to approximately 247,000 affected women and 157,000 affected men.
 DISCUSSION
There are published estimates of the size of the CHD-affected population in the US in the 
year 2000.13,15,16 A task force that convened as part of the American College of 
Cardiology’s 32nd Bethesda Conference estimated that in the year 2000, the total number of 
adults living with CHD in the United States was approximately 788,000 – a combination of 
adults with simple (368,800), moderate (302,500) and complex CHD (117,000) – based on 
estimates of the birth prevalence and survival from the New England Regional Infant 
Cardiac Program.16,20 Subsequently, Hoffman and colleagues15 refined these estimates 
under two extreme scenarios. If all individuals born with CHD were treated, they estimated 
approximately 1.3 million adult survivors - 750,000 with simple CHD and 580,000 with 
moderate or complex CHD; without treatment, the number of survivors in each group would 
be 400,000 and 250,000 respectively.15 Marelli and colleagues, in 2007, published estimates 
of the lifetime prevalence of CHD in Québec in 200012 categorized by those with “severe” 
CHD and all other CHD. The proportion of the population with severe CHD was smaller 
(9%) than the 15% with complex CHD estimated by Hoffman and colleagues in 200415 
primarily due to differences in the specific CHD included in the respective categories. In 
2009, Marelli and colleagues extrapolated that lifetime prevalence estimate to the US 
population in 2000 and estimated approximately 1.7 million affected individuals, evenly 
divided among adults and children.13
Importantly, the current study is an extension of Marelli’s 2009 analysis, using updated 2010 
Québec estimates as input data,17 and attempts to account for racial-ethnic differences in 
survival in the US. Analyses of cross-sectional US death certificate data have shown that 
age-adjusted mortality due to CHD is greater for non-Hispanic Blacks than non-Hispanic 
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whites and that decreases in mortality due to CHD have been greatest for non-Hispanic 
whites compared to other racial-ethnic groups in the US.9 In addition, survival analyses of 
population-based birth defects surveillance data have shown that mortality in ages 0 to 5 
among non-Hispanic black and Hispanic infants born with CHD is generally higher than 
among non-Hispanic whites, although there are differences among CHD subtypes.11,18 The 
reasons for higher mortality among those age 0 to 5 born with a CHD in minority 
populations are not well understood; although differential access to healthcare among 
minority populations has frequently been a proposed explanation, it is likely not the only 
explanation. For example, there are persistent racial-ethnic differences in post-operative 
mortality after CHD surgery that do not seem to be explained by differences in access to 
care.21 Nembhard and colleagues18 have hypothesized that other factors, such as the severity 
of the defect, use of home care both before and after surgery, and differences in the 
frequency and severity of comorbid conditions such as asthma, could be responsible for 
racial-ethnic differences in mortality among those age 0 to 5 with CHD. Previous reports of 
the size of the population living with CHD have not attempted to account for these 
recognized, but largely unexplained, differences in child survival.
Conceptually, the lifetime prevalence of CHD in a closed population (i.e., no migration) or 
in a population with zero net migration is the product of the birth prevalence and survival. 
The estimated birth prevalence of CHD in the US is approximately 8–10 per 1,000 live 
births1,2 and has increased over the last 30–40 years, driven largely by increasing prevalence 
and improved detection of less severe phenotypes such as ventricular septal defects and 
atrial septal defects.22,23 Survival, however, has also increased because of advancements in 
medical and surgical care. According to US death certificate data, age adjusted annual infant 
mortality due to CHD decreased 40% between 1979 and 19938 and continued to decrease 
through the mid-2000s9 although death from CHD still remains the most common cause of 
infant mortality from birth defects in the US.24 In addition, according to death certificates, 
overall mortality decreased 40% in people with tetralogy of Fallot and 60% in those with 
ventricular septal defect between 1980 and 2005.25 Similarly, in the Québec CHD database, 
among over 8,000 patients with severe CHD followed for over 1 million life-years, the 
median age of death increased from two years of age in 1987–1993 to 23 years of age in 
1999–2005.14 The authors concluded that mortality from CHD has changed from a bimodal 
distribution of death to a distribution skewed towards the elderly, matching that of the 
population unaffected by CHD.14 Finally, with respect to sex, it has been observed that 
among adults aged 18–45 years with CHD, women had lower in-hospital mortality than 
men, independent of pregnancy history.26
Despite the fact that most CHD patients require lifelong cardiology care,27 data from a 
recent study indicated that over 40% of individuals with CHD reported a gap of at least three 
years in such care28 with the late teens being the most common age of the first gap. This 
corresponds to the typical time of transition from pediatric to adult oriented medical care 
during which pediatric patients can be lost to follow-up and fail to undergo a successful 
transition.28,29 A long lapse in medical care may result in adverse outcomes, since adults 
with CHD (ACHD) must be monitored frequently for the development of complications 
from their structural heart defects, such as arrhythmias and pulmonary hypertension.29,30 As 
of 2010, the consensus among the ACHD community was that the ACHD clinics in the US 
Gilboa et al. Page 6













at that time were inadequate to meet the needs of this population.29 The treatment 
recommendations from the 32nd Bethesda Conference were that adults with moderate or 
complex CHD should be followed in a regional ACHD center at least once or twice each 
year.16 Based on the 2009 estimate of nearly 860,000 adults with CHD in the US in the year 
2000, and assuming that 50% of them were seen at least once each year in an ACHD 
regional center, it was estimated that 150 large regional centers would be required to care for 
the ACHD population in the US.13 If the current estimate of 1.4 million adults with CHD in 
2010 is considered, it represents a 63% increase in the estimated size of the adult population 
with CHD in the US since the year 2000. It is conceivable that over 200 ACHD regional 
centers will be required to meet the needs of this rapidly growing population. According to 
the Adult Congenital Heart Association, currently there are 114 ACHD regional centers in 
the United States (http://www.achaheart.org/home/clinic-directory.aspx - Accessed 12 
February 2015).
The study findings presented here must be interpreted in light of several potential 
methodological limitations. First, the Canadian input prevalence data were derived from 
administrative data in which CHD were identified via ICD-9 coding; cases identified in this 
fashion are more subject to misclassification than those actively ascertained through medical 
records review.10 However, to minimize the possibility of misclassification resulting from 
the use of administrative data, Marelli and colleagues developed extensive algorithms to 
exclude individuals who seemed to have miscoded CHD and manually reviewed 
approximately 28% of their original dataset (17,474/61,386) to validate the algorithm’s 
categorization.12 In addition, the input data for the current analysis17 reassuringly had a 
CHD birth prevalence comparable those reported from active birth defects surveillance 
systems.2 An advantage of using input data derived from inpatient hospitalization and 
outpatient records across the lifespan, is that individuals with CHD who were clinically 
diagnosed at any age were included in the dataset, and diagnosis at birth (which can be 
missed depending on the CHD subtype) was not required for inclusion. Second, given that 
individuals who neither represent a visible racial-ethnic minority nor consider themselves 
Aboriginal represent 89% of the Québec population according to the 2011 Canadian 
National Household Survey,31 the calculated age-, sex- and severity-specific prevalences for 
2010 in Québec were assumed to be equivalent to that of the US non-Hispanic white 
population for the same time period. We assumed there were no differences in either birth 
prevalence or survival between the Québec population and the US non-Hispanic white 
population with CHD. Any differences in environmental or genetic risk factors or health care 
provision between Canada and the US were assumed to have no impact on prevalence or 
survival. Third, for individuals six years of age and older, we assumed the impact of 
mortality due to CHD was the same across all age groups. For children 0–5 years, we 
approximated CHD racial-ethnic prevalence ratios using their corresponding ratios of 
cumulative survival with CHD thereby assuming no racial-ethnic differences in CHD 
prevalence at birth. Given that racial-ethnic differences in CHD prevalence in the US are 
inconsistent across CHD subtypes and eras,22,23,32 accounting for differences in birth 
prevalence across racial-ethnic groups was not feasible in this study. Other nuances of 
differential survival by race-ethnicity could not be modeled. For example, recently published 
data from California pediatric cardiology specialty care centers indicated substantial 
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differences in hospital discharges among Hispanics and non-Hispanic whites over a 28-year 
period.33 From 1983–2011, the percent of discharges identified as non-Hispanic white 
decreased from 58% to 30%; in the same time period, the percent identified as Hispanic rose 
from 24% to 48%. This demographic shift, specific to California, might be attributable to 
underlying population growth, immigration, or changing access to health care.
Despite these limitations, this is the first report to provide a contemporary estimate of the 
number of people living with CHD in the US stratified by age, sex, race-ethnicity and CHD 
severity. Compared with population estimates generated for the year 2000,13 the current 
estimates for the year 2010 represent a 40% increase in the total number of individuals living 
with CHD in the US and over a 60% increase in the size of the adult population alone. 
Results from this analysis can help inform two efforts critical to this emergent public health 
issue: (1) planning for health services delivery to meet the needs of the growing population 
of adults with CHD and; (2) the development of surveillance data across the lifespan to 
provide more accurate, empirical estimates of the prevalence of CHD across all age groups 
in the US.
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• There are no current empirical data documenting the number of people 
living with congenital heart defects (CHD) in the United States (US).
• The aim of this study was to estimate the CHD prevalence across all 
age groups in the US in the year 2010. Using prevalence data from 
Québec, Canada in the year 2010 as a foundation for a mathematical 
model, we estimated that approximately 2.4 million people (1.4 million 
adults, 1 million children) were living with CHD in the US in the year 
2010. Nearly 300,000 people had severe CHD.
• Overall, there was a slight predominance of females compared to 
males.
What are the clinical implications?
• This current estimate of 1.4 million adults with CHD in 2010 
corresponds to a 63% increase in the estimated size of the adult 
population with CHD since the year 2000.
• Resource allocation for health services delivery will need to account for 
this growing population of adults with CHD.
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Flow chart illustrating input data, age and race-ethnicity specific mortality adjustments, and 
data outputs for the estimation of congenital heart defects (CHD) prevalence in the United 
States in 2010
The oval-shaped model inputs and estimates are considered to be subject to sampling 
variability. The rectangular-shaped population count input node is considered known.
The shaded nodes represent estimates produced by the modeling process while non-shaded 
nodes represent either model inputs or intermediate steps.
NHW, Non-Hispanic White; NHB, Non-Hispanic Black
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TABLE 1
Estimated prevalence of congenital heart defects (CHD) for individuals of all ages, among children (0–17 
years), and among adults (18 years and older) by severity, and by race-ethnicity in the United States, 2010
Age Group CHD Severity
Estimated US Prevalence per 1,000 (95% 
Confidence Interval)
Estimated Number of Individuals (95% 
Confidence Interval)*
All ages Overall 7.85 (7.79 – 7.92) 2,425,000 (2,405,000 – 2,444,000)
Severe 0.92 (0.90 – 0.94) 283,000 (277,000 – 290,000)
Children Overall 13.21 (13.03 – 13.39) 980,000 (966,000 – 993,000)
Severe 1.66 (1.60 – 1.73) 123,000 (119,000 – 128,000)
Adults Overall 6.16 (6.10 – 6.22) 1,444,500 (1,431,000 – 1,459,000)
Severe 0.68 (0.66 – 0.70) 160,000 (155,000 – 165,000)
Age Group Race-Ethnicity
Estimated US Prevalence per 1,000 (95% 
Confidence Interval)
Estimated Number of Individuals (95% 
Confidence Interval)*
Children Non-Hispanic White 13.31 (13.12 – 13.49) 620,000 (612,000 – 629,000)
Non-Hispanic Black 12.69 (12.50 – 12.88) 133,000 (131,000 – 135,000)
Hispanic 13.26 (13.08 – 13.45) 227,000 (224,000 – 230,000)
Adults Non-Hispanic White 6.36 (6.29 – 6.42) 1,104,000 (1,094,000 – 1,115,000)
Non-Hispanic Black 5.63 (5.56 – 5.69) 155,000 (153,000 – 156,000)
Hispanic 5.58 (5.52 – 5.65) 186,000 (184,000 – 188,000)
US, United States
*
Rounded to the nearest 1,000; any minor inconsistencies between Table 1 and Table 2 are because estimates are the rounded mean values from 
10,000 simulations.
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TABLE 2
Sex-, age-group, and severity-specific estimates of prevalence of congenital heart defects (CHD) in the United 
States, 2010
Age Group (y) CHD Severity
Estimated US Prevalence per 1,000 (95% 
Confidence Interval)
Estimated Number of Individuals (95% 
Confidence Interval)*
Females
0 to 5 Overall 11.54 (11.12 – 11.96) 137,000 (132,000 – 142,000)
Severe 1.07 (0.95 – 1.20) 13,000 (11,000 – 14,000)
6 to 12 Overall 15.57 (15.11 – 16.05) 218,000 (212,000 – 225,000)
Severe 1.69 (1.53 – 1.84) 24,000 (21,000 – 26,000)
13 to 17 Overall 12.62 (12.15 – 13.08) 130,000 (126,000 – 135,000)
Severe 1.87 (1.70 – 2.05) 19,000 (18,000 – 21,000)
18 to 24 Overall 6.35 (6.08 – 6.62) 95,000 (91,000 – 99,000)
Severe 1.33 (1.20 – 1.45) 20,000 (18,000 – 22,000)
25 to 44 Overall 6.01 (5.86 – 6.16) 247,000 (241,000 – 253,000)
Severe 1.13 (1.06 – 1.19) 46,000 (43,000 – 49,000)
45 and older Overall 6.70 (6.58 – 6.81) 433,000 (426,000 – 441,000)
Severe 0.41 (0.38 – 0.44) 26,000 (25,000 – 28,000)
All ages Overall 8.03 (7.94 – 8.13) 1,261,000 (1,246,000 – 1,275,000)
Severe 0.95 (0.91 – 0.98) 148,000 (143,000 – 153,000)
Males
0 to 5 Overall 13.96 (13.52 – 14.42) 173,000 (167,000 – 179,000)
Severe 1.45 (1.30 – 1.59) 18,000 (16,000 – 20,000)
6 to 12 Overall 14.33 (13.89 – 14.78) 210,000 (204,000 – 217,000)
Severe 2.00 (1.84 – 2.17) 29,000 (27,000 – 32,000)
13 to 17 Overall 10.18 (9.78 – 10.59) 111,000 (107,000 – 115,000)
Severe 1.85 (1.68 – 2.03) 20,000 (18,000 – 22,000)
18 to 24 Overall 5.05 (4.82 – 5.29) 79,000 (75,000 – 83,000)
Severe 1.11 (1.00 – 1.22) 17,000 (16,000 – 19,000)
25 to 44 Overall 3.83 (3.71 – 3.95) 157,000 (153,000 – 162,000)
Severe 0.76 (0.71 – 0.81) 31,000 (29,000 – 33,000)
45 and older Overall 7.59 (7.46 – 7.72) 434,000 (426,000 – 441,000)
Severe 0.33 (0.30 – 0.36) 19,000 (17,000 – 20,000)
All ages Overall 7.67 (7.58 – 7.76) 1,164,000 (1,150,000 – 1,177,000)
Severe 0.89 (0.86 – 0.92) 135,000 (130,000 – 140,000)
y, years
*
Rounded to the nearest 1,000; any minor inconsistencies between Table 1 and Table 2 are because estimates are the rounded mean values from 
10,000 simulations.
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